Deadline: 3 March 2025
The Lung Cancer Research Foundation is inviting proposals to focus on the science behind HER2 alterations as oncogenic drivers of malignancy and/or the development of novel therapeutic approaches for patients with tumors harboring HER2 mutations and/or other HER2 alterations.
Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across the care continuum and have the potential to increase survivorship. Given the specific interest in the development of novel therapies for this group of patients, it is preferred that a clinical trial be associated with or planned as a result of the findings of the project. It is also expected that a program of correlative, translational research will be proposed that will enhance the understanding of these oncogenic-driven lung cancers.
Focus Areas
- They encourage applications on a wide variety of topics related to HER2 alterations and lung cancer, including but not limited to the following:
- The proposal must be associated with a clinical trial, either ongoing or planned as a result of the project. The trial can investigate novel treatment approaches, new therapies (i.e. next generation drugs or agents with novel mechanisms of action), and novel combinations. Therapy can include targeted agents (TKIs), antibody-drug conjugates, immunotherapies, cell therapies etc. if there is a reasonably strong rationale supporting the investigation.
- The proposal must have a program of basic and/or translational work associated with the clinical trial. Topics of interest can include but are not limited to mechanisms of primary or secondary resistance, studies on the immune landscape and tumor microenvironment, biology and mechanisms of tumor progression, identification of biomarkers to predict sensitivity to specific therapies, methods for optimizing treatment (efficacy and/or tolerability), etc.
- The proposal must include studies in patients with lung cancer harboring HER2- mutations and/or other HER2 alterations.
- A patient/patient advocate needs to be part of the research team applying for the grant and that this individual should have a role in the design of the research.
Funding Information
- The maximum award amount is $500,000 for a period of two years ($250,000 per year).
Eligibility Criteria
- Investigators must be affiliated with a non-profit, academic or research institution. An applicant must have a postdoctoral or clinical research fellow appointment and/or a faculty position and may have any level of research experience.
- Applicants from US-based and international institutions are eligible to apply and may hold any residency/citizenship status. Applicants are prohibited from applying in more than one of LCRF’s funding tracks in the same cycle.
Evaluation Criteria
- Submissions will be evaluated for sound scientific rationale, study design, feasibility, and creativity/innovation. Reviewers at the full proposal will be asked to provide an impact score reflecting their assessment of the likelihood for the project to exert a sustained, powerful influence on the field of lung cancer research.
For more information, visit LCRF.
